share_log

SenesTech | 424B5: Prospectus

SEC ·  Jun 21 04:03

Summary by Moomoo AI

SenesTech, Inc., a company specializing in the development of technology for managing animal pest populations through fertility control, has announced an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, dated June 20, 2024. Under this agreement, SenesTech may offer and sell up to $1,575,944 of its common stock. The sales may be conducted through various methods deemed to be an 'at-the-market' offering as defined by the Securities Act of 1933. This includes sales made directly on the Nasdaq Capital Market, where SenesTech's common stock is listed under the symbol 'SNES.' The last reported sale price of SenesTech's common stock on Nasdaq was $0.6011 per share as of June 18, 2024. The offering will terminate upon the earlier of the sale...Show More
SenesTech, Inc., a company specializing in the development of technology for managing animal pest populations through fertility control, has announced an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, dated June 20, 2024. Under this agreement, SenesTech may offer and sell up to $1,575,944 of its common stock. The sales may be conducted through various methods deemed to be an 'at-the-market' offering as defined by the Securities Act of 1933. This includes sales made directly on the Nasdaq Capital Market, where SenesTech's common stock is listed under the symbol 'SNES.' The last reported sale price of SenesTech's common stock on Nasdaq was $0.6011 per share as of June 18, 2024. The offering will terminate upon the earlier of the sale of common stock reaching the aggregate sales price of $1,575,944 or the termination of the Sales Agreement by either SenesTech or Wainwright. The company plans to use the net proceeds from this offering for general corporate purposes, which may include research and development expenses, capital expenditures, working capital, and general and administrative expenses.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more